Expert Ratings for Halozyme Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Halozyme Therapeutics (NASDAQ:HALO) received 2 bullish, 1 somewhat bullish, and 1 indifferent rating from analysts. The company's average 12-month price target is $56.75, which has increased by 3.8% over the past month.
August 15, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics received positive ratings from analysts, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. The positive ratings for Halozyme Therapeutics, along with an increased price target, suggest a positive outlook for the company's stock. This could lead to increased demand for the stock, potentially driving the price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100